306 related articles for article (PubMed ID: 27626702)
1. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
[TBL] [Abstract][Full Text] [Related]
2. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
[TBL] [Abstract][Full Text] [Related]
3. TNFR2: A Novel Target for Cancer Immunotherapy.
Vanamee ÉS; Faustman DL
Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
[TBL] [Abstract][Full Text] [Related]
4. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
5. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
[TBL] [Abstract][Full Text] [Related]
6. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
Chopra M; Riedel SS; Biehl M; Krieger S; von Krosigk V; Bäuerlein CA; Brede C; Jordan Garrote AL; Kraus S; Schäfer V; Ritz M; Mattenheimer K; Degla A; Mottok A; Einsele H; Wajant H; Beilhack A
Carcinogenesis; 2013 Jun; 34(6):1296-303. PubMed ID: 23385062
[TBL] [Abstract][Full Text] [Related]
8. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
9. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
Twu YC; Gold MR; Teh HS
Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
[TBL] [Abstract][Full Text] [Related]
10. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
11. An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability
Urbano PCM; Koenen HJPM; Joosten I; He X
Front Immunol; 2018; 9():573. PubMed ID: 29619032
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
Zou H; Li R; Hu H; Hu Y; Chen X
Front Immunol; 2018; 9():594. PubMed ID: 29632537
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
14. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages.
Ruspi G; Schmidt EM; McCann F; Feldmann M; Williams RO; Stoop AA; Dean JL
Cell Signal; 2014 Apr; 26(4):683-90. PubMed ID: 24378531
[TBL] [Abstract][Full Text] [Related]
15. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
16. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
Salomon BL; Leclerc M; Tosello J; Ronin E; Piaggio E; Cohen JL
Front Immunol; 2018; 9():444. PubMed ID: 29593717
[TBL] [Abstract][Full Text] [Related]
17. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
18. TNFR2 deficiency impairs the growth of mouse colon cancer.
Li P; Yang Y; Yang X; Wang Y; Chou CK; Jiang M; Zheng J; Chen F; Chen X
Int J Biol Sci; 2023; 19(4):1024-1035. PubMed ID: 36923938
[No Abstract] [Full Text] [Related]
19. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
[TBL] [Abstract][Full Text] [Related]
20. TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF-κB pathway.
Wang J; Ferreira R; Lu W; Farrow S; Downes K; Jermutus L; Minter R; Al-Lamki RS; Pober JS; Bradley JR
Sci Rep; 2018 Aug; 8(1):12079. PubMed ID: 30104686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
